Terconazole
From Wikipedia, the free encyclopedia
 |
|
|
Terconazole
|
|
| Systematic (IUPAC) name | |
| 1-[4-[ [(2S,4S)-2-(2,4-Dichlorophenyl)-2- (1,2,4-triazol-1-ylmethyl)- 1,3-dioxolan-4-yl]methoxy]phenyl]- 4-propan-2-yl-piperazine | |
| Identifiers | |
| CAS number | |
| ATC code | G01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C26H31Cl2N5O3 |
| Mol. mass | 532.462 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 94.9% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Terconazole is an anti-fungal medication, primarily used to treat vaginal fungal infections.
[edit] References
 |
This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||
